Literature DB >> 16723601

In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.

Hee-Soo Park1, Hyun-Joo Kim, Min-Jung Seol, Dong-Rack Choi, Eung-Chil Choi, Jin-Hwan Kwak.   

Abstract

DW-224a showed the most potent in vitro activity among the quinolone compounds tested against clinical isolates of gram-positive bacteria. Against gram-negative bacteria, DW-224a was slightly less active than the other fluoroquinolones. The in vivo activities of DW-224a against gram-positive bacteria were more potent than those of other quinolones.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723601      PMCID： PMC1479124          DOI： 10.1128/AAC.01407-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Role of newer fluoroquinolones in lower respiratory tract infections.

Authors:  H Lode; M Allewelt
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

Review 2.  Antibacterial resistance worldwide: causes, challenges and responses.

Authors:  Stuart B Levy; Bonnie Marshall
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

3.  In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.

Authors:  J I Oh; K S Paek; M J Ahn; M Y Kim; C Y Hong; I C Kim; J H Kwak
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 4.  Vancomycin resistance: status quo and quo vadis.

Authors:  H P Endtz; N van den Braak; H A Verbrugh; A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-10       Impact factor: 3.267

Review 5.  The quinolones: decades of development and use.

Authors:  A M Emmerson; A M Jones
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

Review 6.  Adverse drug reactions: implications for the development of fluoroquinolones.

Authors:  Peter Ball
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

7.  High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999.

Authors:  Jan M Bell; John D Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.

Authors:  Angela M Nilius; Linus L Shen; Dena Hensey-Rudloff; Laurel S Almer; Jill M Beyer; Darlene J Balli; Yingna Cai; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).

Authors:  Jae-Hoon Song; Sook-In Jung; Kwan Soo Ko; Na Young Kim; Jun Seong Son; Hyun-Ha Chang; Hyun Kyun Ki; Won Sup Oh; Ji Yoeun Suh; Kyong Ran Peck; Nam Yong Lee; Yonghong Yang; Quan Lu; Anan Chongthaleong; Cheng-Hsun Chiu; M K Lalitha; Jennifer Perera; Ti Teow Yee; Gamini Kumarasinghe; Farida Jamal; Adeeba Kamarulzaman; Navaratnam Parasakthi; Pham Hung Van; Celia Carlos; Thomas So; Tak Keung Ng; Atef Shibl
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
  9 in total
  14 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 2.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 3.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

4.  In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus.

Authors:  Sang-Hun Oh; Hee-Soo Park; Jun-Hyung Lee; Sung-Yun Baek; Sang-Eun Chae; Kyuman Oh; Young Lag Cho; Jin-Hwan Kwak
Journal:  Molecules       Date:  2017-11-29       Impact factor: 4.411

Review 5.  Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.

Authors:  Yang Liu; Yan Zhang; Wanyu Zhao; Xiaolei Liu; Fengjuan Hu; Birong Dong
Journal:  Front Pharmacol       Date:  2019-10-31       Impact factor: 5.810

Review 6.  Pipeline of Known Chemical Classes of Antibiotics.

Authors:  Cristina d'Urso de Souza Mendes; Adelaide Maria de Souza Antunes
Journal:  Antibiotics (Basel)       Date:  2013-12-06

Review 7.  Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.

Authors:  Bela Kocsis; J Domokos; D Szabo
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-23       Impact factor: 3.944

8.  Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial.

Authors:  Chin Kook Rhee; Jung Hyun Chang; Eu Gene Choi; Hyun Kuk Kim; Yong-Soo Kwon; Sun Young Kyung; Ji-Hyun Lee; Myung Jae Park; Kwang Ha Yoo; Yeon Mok Oh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-22

Review 9.  The Continuing Threat of Methicillin-Resistant Staphylococcus aureus.

Authors:  Márió Gajdács
Journal:  Antibiotics (Basel)       Date:  2019-05-02

Review 10.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.